What is the role of drotrecogin alfa (activated protein C) in the treatment of multiple organ dysfunction syndrome (MODS) in sepsis?

Updated: Jan 27, 2020
  • Author: Ali H Al-Khafaji, MD, MPH, FACP, FCCP, FCCM; Chief Editor: Michael R Pinsky, MD, CM, Dr(HC), FCCP, FAPS, MCCM  more...
  • Print

Drotrecogin alfa (activated protein C) was the only widely accepted drug specific to the therapy of sepsis. However, in a clinical trial (PROWESS-SHOCK trial), this agent failed to show a survival benefit for patients with severe sepsis and septic shock. The results of the trial led to the withdrawal of drotrecogin alfa from the worldwide market on October 25, 2011. The adverse side effect of drotrecogin alfa is bleeding.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!